The proposed transaction will involve an initial exchange of Bacterin common stock, valued at $1 million at the closing date, in exchange for all the assets of RMS, including approximately $500,000 of inventory, existing commercial agreements and intellectual property. In addition, upon the achievement of certain revenue goals by RMS over a two-year period, additional Bacterin common stock valued at $1 million may be remitted to RMS. The letter of intent is subject to final due diligence, the execution of definitive purchase documents and the approval of both companies’ boards of directors.
Read the news release about Bacterin and Robinson MedSurg.
Read other coverage about supply chain news:
– Amerinet, St. John Companies Sign Agreement for Diagnostic Imaging Supplies
– Medtronic CFO Dispels Rumors Company Is Shying Away From GPOs
– Healthcare Organizations Struggle to Invest in Stronger Medical Equipment for Heavier Patients
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
